Daily Anesthesiology Research Analysis
Three impactful anesthesiology-related studies stood out: a phase 3 randomized trial showed a full-spectrum Cannabis sativa extract modestly reduced chronic low back pain with acceptable safety; a methodological meta-analysis demonstrated intrinsic selection bias in observational studies of early salvage therapies in critical care; and a double-blind randomized trial found cipepofol provided non-inferior sedation to etomidate–propofol in older adults undergoing endoscopy with faster discharge re
Summary
Three impactful anesthesiology-related studies stood out: a phase 3 randomized trial showed a full-spectrum Cannabis sativa extract modestly reduced chronic low back pain with acceptable safety; a methodological meta-analysis demonstrated intrinsic selection bias in observational studies of early salvage therapies in critical care; and a double-blind randomized trial found cipepofol provided non-inferior sedation to etomidate–propofol in older adults undergoing endoscopy with faster discharge readiness and less injection pain.
Research Themes
- Analgesia innovation for chronic pain
- Methodological rigor and bias in critical care timing studies
- Geriatric procedural sedation optimization
Selected Articles
1. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
In a multicenter phase 3 RCT (n=820), a full-spectrum cannabis extract (VER-01) produced a statistically significant, modest reduction in chronic low back pain versus placebo over 12 weeks and improved neuropathic pain symptoms in a predefined subgroup. Adverse events were more frequent but mainly mild-to-moderate, and no dependence or withdrawal was observed.
Impact: First large phase 3 randomized trial to show efficacy and tolerability of a full-spectrum cannabis extract for chronic low back pain, informing pain management strategies.
Clinical Implications: VER-01 may be considered as an adjunct or alternative in multimodal chronic low back pain management, with counseling on modest effect size, higher mild-to-moderate AEs, and close monitoring. Health systems should weigh potential benefits against costs and regulatory considerations.
Key Findings
- Met the primary endpoint: mean NRS pain reduction −1.9 with VER-01; MD vs placebo −0.6 (95% CI −0.9 to −0.3; P<0.001).
- Neuropathic pain subgroup: NPSI decreased −14.4; MD vs placebo −7.3 (95% CI −13.2 to −1.3; P=0.017).
- Randomized withdrawal phase did not meet primary endpoint (HR 0.75; P=0.288), but pain increased more with placebo upon withdrawal (MD 0.5; P=0.034).
- Adverse events were more frequent with VER-01 (83.3% vs 67.3%) but were mostly mild-to-moderate and transient; no dependence/withdrawal observed.
Methodological Strengths
- Multicenter, double-blind, randomized, placebo-controlled phase 3 design.
- Predefined neuropathic pain subgroup and randomized withdrawal phase to probe durability.
Limitations
- Effect size was modest (MD −0.6 on NRS).
- Higher overall adverse event rates versus placebo; long-term safety beyond study duration not fully established.
Future Directions: Conduct head-to-head comparisons with standard analgesics, evaluate functional outcomes and cost-effectiveness, and assess long-term safety and dependency risk in broader populations.
Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04940741 .
2. Observational studies of early versus late salvage therapies in critical care exhibit intrinsic selection bias: two meta-analyses.
Across 72 RRT and 50 IMV studies, observational designs frequently yielded conclusions discordant with randomized evidence about the timing of salvage therapies, largely attributable to selection bias (e.g., conditioning on treatment receipt). Findings caution against relying on observational timing data to change practice.
Impact: Provides rigorous evidence of systematic bias in widely cited observational timing studies, guiding clinicians and researchers toward randomized, criteria-driven trials for critical-care interventions.
Clinical Implications: Do not base early/late initiation policies for RRT or IMV on observational timing studies alone. Design and prioritize randomized trials with objective, pre-specified eligibility and timing criteria; consider target trial emulation when RCTs are infeasible.
Key Findings
- RRT: Observational studies suggested mortality benefit of early RRT (OR 0.52), but experimental studies did not (OR 0.94).
- IMV: Observational studies showed harm with early IMV (OR 1.25); experimental studies also suggested harm (OR 1.86), though with wide CI.
- Conditioning observational cohorts on receipt of IMV biased results towards apparent benefit of early IMV (OR 0.75) versus studies including non-intubated patients (OR 1.63 harm).
Methodological Strengths
- Parallel meta-analyses contrasting observational versus experimental designs across two salvage therapies.
- Identification and quantification of selection bias mechanisms (conditioning on treatment).
Limitations
- Heterogeneity of definitions and protocols across included studies; limited number of experimental IMV trials.
- Aggregated data meta-analyses without patient-level adjustment for all confounders.
Future Directions: Conduct randomized trials with standardized, objective timing criteria; apply target trial emulation frameworks; improve reporting standards to mitigate immortal time and selection biases.
BACKGROUND: It is difficult to determine the optimal timing of salvage therapies, such as initiation of renal replacement therapies (RRT), using non-experimental designs. Therefore, using timing of RRT as a motivating example, we performed meta-analyses comparing observational and experimental studies assessing timing of RRT and timing of invasive mechanical ventilation (IMV). METHODS: We performed two meta-analyses of observational and experimental studies testing the association of early versus late initiation of RRT and IMV on mortality. RESULTS: We included 72 studies for RRT (57 observational, 15 experimental) and 50 for IMV (48 observational, 2 experimental). For RRT, observational studies showed mortality benefit with early RRT (OR 0.52, 95% CI 0.42-0.63) that was not seen in experimental studies (OR 0.94, 95% CI 0.76-1.17). For IMV, observational studies demonstrated harm with early IMV (OR 1.25, 95% CI 1.03-1.52), although not to the degree of experimental studies (OR 1.86, 95% CI 0.90-3.86). When observational studies were restricted to subjects who all received IMV, conclusions were further biased towards benefit favoring early IMV (OR 0.75, 95% CI 0.55-1.02). Studies that also included subjects who were never intubated showed harm with early IMV (OR 1.63, 95% CI 1.30-2.04). CONCLUSIONS: There were significant differences in the results of observational and experimental studies looking at timing of salvage therapies, partly due to selection bias in observational studies. This issue was worsened by only including subjects who receive the therapy. Randomized trials using objective eligibility criteria remain the best method to determine optimal timing of salvage therapies.
3. Safety and efficacy of cipepofol for painless digestive endoscopy in older patients: a randomized, double-blind, non-inferiority trial.
In older adults undergoing gastroscopy or colonoscopy, cipepofol provided non-inferior sedation duration and similar safety to etomidate–propofol, with faster discharge readiness and no injection pain. Hemodynamic stability and adverse event rates were comparable across groups.
Impact: Introduces a practical alternative sedative for older patients, demonstrating non-inferior efficacy with operational advantages (faster discharge readiness and less injection pain).
Clinical Implications: Cipepofol can be considered as a streamlined option for painless digestive endoscopy in older adults, potentially improving throughput and patient comfort while maintaining safety. Institutions should evaluate formulary, training, and cost implications.
Key Findings
- Sedation success was 100% in both groups; initial sedation duration was comparable (P=0.165).
- Discharge readiness time was shorter with cipepofol (median 1.67 vs 2.96 minutes; P=0.002).
- Adverse events (hypotension, bradycardia, hypoxia) and hemodynamics were similar; injection pain occurred only with etomidate–propofol (5%).
Methodological Strengths
- Randomized, double-blind, non-inferiority design focused on older adults.
- Clear operational endpoints (discharge readiness) alongside safety and efficacy.
Limitations
- Single-center study with modest sample size limits generalizability.
- Not powered for rare adverse events; limited to digestive endoscopy context.
Future Directions: Multicenter trials across diverse settings and procedures, pharmacoeconomic analyses, and evaluation in frailty subgroups are warranted.
BACKGROUND: Cipepofol, a novel anesthetic agent, may offer advantages for older patients undergoing painless digestive endoscopy. This study evaluated the safety and efficacy of this approach compared to a combination of etomidate and propofol (EP). METHODS: In this single-center, double-blind, randomized, non-inferiority trial, 120 older patients(aged 65-90 years) undergoing painless gastroscopy or colonoscopy were randomized to receive either cipepofol (0.3-0.4 mg/kg; n = 60) or EP (1:1 ratio, 0.15-0.2 mL/kg; n = 60). Primary outcomes included sedation duration. Secondary outcomes assessed sedation success, recovery time, discharge readiness, adverse events, and hemodynamic stability. RESULTS: All patients achieved successful sedation (100%). Initial sedation duration was comparable between the cipepofol and EP groups (8.73 [5.10, 10.18] vs. 7.41 [5.35, 9.09] minutes; p = 0.165). Recovery times were similar (5.49 [3.51, 7.62] vs. 4.86 [3.36, 8.86] minutes; p = 0.819), while discharge readiness was faster in the cipepofol group (1.67 [0.78, 2.38] vs. 2.96 [1.21, 7.23] minutes; p = 0.002). Adverse events, including hypotension, bradycardia, and hypoxia, were comparable. Injection pain occurred only in the EP group (5%). CONCLUSION: In older patients undergoing painless digestive endoscopy, cipepofol is non-inferior to the etomidate-propofol combination in sedation duration and safety. It also shares the characteristic of stable hemodynamics and offers advantages, including reduced injection pain and a shorter time to meet discharge criteria, providing a simplified choice for clinical practice. TRIAL REGISTRATION: ChiCTR2400088889, Date of Registration: 2024-08-28, https://www.chictr.org.cn/showproj.html?proj=212632 .